Alligator Sells Mitazalimab for $750,000 Upfront and Contingent Upside

Alligator Bioscience has agreed to sell worldwide rights and assets for mitazalimab to Biossil, trading a modest upfront payment for contingent milestones, royalties and relief from future program costs.

Biossil will pay $750,000 upfront. Alligator could receive up to $3 million when mitazalimab first wins regulatory approval in the United States and European Union, plus up to $105 million tied to worldwide net sales. The company is also eligible for a mid-single-digit royalty on global net sales, with total royalties capped at $250 million.

Those headline amounts are not guaranteed transaction value. Every payment other than the upfront amount depends on future events, and Alligator explicitly said there is no assurance that the milestones or royalties will be received. If Biossil sells or licenses mitazalimab to a third party within two years, Alligator will receive a share of those proceeds, although the percentage was not disclosed.

Biossil is acquiring the patents, clinical and regulatory data, know-how, manufacturing materials and drug inventory. After closing, it will assume development, manufacturing and patent costs and has committed to continue development.

For Alligator, the immediate benefit is financial focus. Closing would end its costs for maintaining the mitazalimab program and related intellectual property. The company said the upfront proceeds should extend its cash runway and support a strategy centered on its economic interest in the HER2-targeting antibody program HLX22.

The scale of that benefit should not be overstated. A $750,000 upfront payment is small compared with the possible $108 million of contingent milestones, so the transaction does not by itself resolve longer-term funding needs. The sale shifts most development risk and spending to Biossil, but also leaves Alligator dependent on another company for progress and future payments.

Completion remains subject to customary conditions, transfer of assets and documentation, and required third-party consents. The companies expect closing within 30 days of the October 31 signing.

The transaction gives mitazalimab a new owner while preserving some upside for Alligator shareholders. Its near-term value comes mainly from the upfront cash and avoided maintenance costs. The much larger economic potential depends on Biossil advancing the asset through development, regulatory approval and commercial sales.